These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 1574954

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CV 205-502 in acromegaly.
    Chiodini PG, Attanasio R, Cozzi R, Dallabonzana D, Oppizzi G, Orlandi P, Strada S, Liuzzi A.
    Acta Endocrinol (Copenh); 1993 May; 128(5):389-93. PubMed ID: 8100375
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acromegaly with bromocriptine.
    Wang C, Chan V, Yeung RT.
    Aust N Z J Med; 1979 Jun; 9(3):225-32. PubMed ID: 288387
    [Abstract] [Full Text] [Related]

  • 6. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [Abstract] [Full Text] [Related]

  • 7. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ, Harris AG, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [Abstract] [Full Text] [Related]

  • 8. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
    Garcia MB, Koppeschaar HP, Lips CJ, Thijssen JH, Krenning EP.
    J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
    [Abstract] [Full Text] [Related]

  • 9. Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.
    Rau H, Althoff PH, Schmidt K, Badenhoop K, Usadel KH.
    Clin Investig; 1993 May; 71(5):372-8. PubMed ID: 8508007
    [Abstract] [Full Text] [Related]

  • 10. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW, Croughs RJ, Donker GH, Thijssen JH, Schwarz F.
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [Abstract] [Full Text] [Related]

  • 11. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
    Campino C, Szecowka J, Lopez JM, Seron-Ferre M.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
    [Abstract] [Full Text] [Related]

  • 12. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A.
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [Abstract] [Full Text] [Related]

  • 13. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 14. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
    [Abstract] [Full Text] [Related]

  • 15. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T, Nowak S.
    Endokrynol Pol; 1993 Feb; 44(4):455-65. PubMed ID: 8055814
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment.
    Clayton RN, Vrionides Y, Lynch SS, Butt WR, London DR.
    Acta Endocrinol (Copenh); 1978 Nov; 89(3):469-82. PubMed ID: 360752
    [Abstract] [Full Text] [Related]

  • 18. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
    Schwinn G, Dirks H, McIntosh C, Köbberling J.
    Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
    [Abstract] [Full Text] [Related]

  • 19. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests.
    Nortier JW, Croughs RJ, Thijssen JH, Schwarz F.
    Clin Endocrinol (Oxf); 1984 May; 20(5):565-71. PubMed ID: 6744634
    [Abstract] [Full Text] [Related]

  • 20. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC, Molitch ME, Sawin CT, Jackson IM, Biller BJ, Furlanetto R, Reichlin S.
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.